Hydroxy-sphingomyelin 22:1 as a biomarker for healthy aging
AssigneeNestec S.A.
InventorsSebastiano Collino, Ivan Montoliu Roura, Francois-Pierre Martin, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
Life of this patent
Estimating the term…
Loading patent…
AssigneeNestec S.A.
InventorsSebastiano Collino, Ivan Montoliu Roura, Francois-Pierre Martin, Philippe Alexandre Guy, Serge Andre Dominique Rezzi
Estimating the term…
Using NMR/MS based metabonomics and targeted lipidomics approaches the inventors have explored the metabolic phenotypes of aging and longevity in a cohort compromising centenarians, elderly and young adults. The inventors have identified biomarkers for a reduced risk of developing ageing related chronic inflammatory disorders and propose a method of diagnosing a lifestyle that allows delaying and/or avoiding ageing related chronic inflammatory disorders using hydroxy-sphingomyelin SM-OH-22:1 as biomarker.
A method of diagnosing a lifestyle that allows to delay and/or avoid ageing related chronic inflammatory disorders, comprising
A biomarker for the diagnosis of a lifestyle that allows delaying and/or avoiding ageing chronic inflammatory disorders, wherein the biomarker is hydroxy-sphingomyelin (SM-OH) 22:1.
A method for diagnosing (i) a lifestyle that favors the development of ageing related chronic inflammatory disorders, (ii) a lifestyle that is likely to prevent healthy ageing, (iii) a risk for a shortened lifespan, and/or (iv) unhealthier gut microflora-host interactions, comprising
Dependencies are inferred from the claim text.